Ginkgo Bioworks Holdings, Inc. (DNA) stock
DNANYSEBiological Products, (No Diagnostic Substances)Fiscal year ends December 31
Financials through Q2 FY2026, quarter ended Jun 30, 2026Last filing: 10-Q on Nov 9, 2026Score 9/3013% below fair value
$8.44+0.12 (+1.44%)
Close on Nov 18, 2026Market cap $568.35MP/E –Yield –
Ginkgo Bioworks operating income
Operating income is the profit from the core business after operating expenses such as R&D and selling costs, before interest and taxes.
Ginkgo Bioworks's operating income for the twelve months ending Jun 30, 2026 was -$290.69M. For fiscal 2025 it was -$315.28M. The highest annual figure on record is -$71.60M in fiscal 2019.
Annual operating income
| Period | Period end | Value | Change |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | -$315.28M | – |
| FY2024 | Dec 31, 2024 | -$559.76M | – |
| FY2023 | Dec 31, 2023 | -$864.41M | – |
| FY2022 | Dec 31, 2022 | -$2.21B | – |
| FY2021 | Dec 31, 2021 | -$1.83B | – |
| FY2020 | Dec 31, 2020 | -$137.03M | – |
| FY2019 | Dec 31, 2019 | -$71.60M | – |
Quarterly operating income
Change is against the same quarter a year earlier.
| Period | Period end | Value | Change |
|---|---|---|---|
| Q2 FY2026 | Jun 30, 2026 | -$58.55M | – |
| Q1 FY2026 | Mar 31, 2026 | -$71.37M | – |
| Q4 FY2025 | Dec 31, 2025 | -$70.75M | – |
| Q3 FY2025 | Sep 30, 2025 | -$90.02M | – |
| Q2 FY2025 | Jun 30, 2025 | -$58.16M | – |
| Q1 FY2025 | Mar 31, 2025 | -$80.97M | – |
| Q4 FY2024 | Dec 31, 2024 | -$103.61M | – |
| Q3 FY2024 | Sep 30, 2024 | -$55.20M | – |
| Q2 FY2024 | Jun 30, 2024 | -$222.95M | – |
| Q1 FY2024 | Mar 31, 2024 | -$178.00M | – |
| Q4 FY2023 | Dec 31, 2023 | -$178.12M | – |
| Q3 FY2023 | Sep 30, 2023 | -$286.39M | – |
| Q2 FY2023 | Jun 30, 2023 | -$184.15M | – |
| Q1 FY2023 | Mar 31, 2023 | -$215.75M | – |
| Q4 FY2022 | Dec 31, 2022 | -$230.86M | – |
| Q3 FY2022 | Sep 30, 2022 | -$654.94M | – |
| Q2 FY2022 | Jun 30, 2022 | -$647.78M | – |
| Q1 FY2022 | Mar 31, 2022 | -$675.37M | – |
| Q4 FY2021 | Dec 31, 2021 | -$1.68B | – |
| Q3 FY2021 | Sep 30, 2021 | -$26.67M | – |
| Q2 FY2021 | Jun 30, 2021 | -$59.95M | – |
| Q1 FY2021 | Mar 31, 2021 | -$57.12M | – |
| Q4 FY2020 | Dec 31, 2020 | -$55.89M | – |
| Q3 FY2020 | Sep 30, 2020 | -$34.41M | – |
See a number that looks wrong?